EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis

Ran Guo, Dennis Wat, Steven Ho Man Lam, Tommaso Bucci iD, Christopher Tze-Wei Tsang iD, An-Ping Cai, Yap-Hang Chan, Qing-Wen Ren, Jia-Yi Huang, Jing-Nan Zhang, Wen-Li Gu, Ching-Yan Zhu und 4 weitere

European Respiratory Journal · 2025

DOI: 10.1183/13993003.01574-2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Ran Guo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, The University of Hong Kong Shen Zhen Hospital, Shen Zhen, China. Hauptthemen laut MEDLINE: Bronchiectasis, Macrolides, Anti-Bacterial Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanming Project of Medicine in Shenzen Municipality, HKU-SZH Fund for Shenzhen Key Medical Discipline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Macrolide maintenance therapy (MMT) has demonstrated notable efficacy in reducing exacerbation in patients with bronchiectasis, which is a major risk factor for cardiovascular events. However, a comprehensive assessment of the cardiovascular benefits and safety profile of MMT in this population is lacking.

Methods

This territory-wide cohort study analysed patients diagnosed with bronchiectasis in Hong Kong between 2001 and 2018. Patients were classified as MMT receivers or macrolide non-receivers based on the administration of MMT. Propensity score (PS) matching was employed for confounding factors adjustment. The primary outcome of interest was major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction and stroke. The safety outcome was the occurrence of ventricular arrhythmias or sudden cardiac death. Cox proportional hazard regression analysis was utilised to compare the incidence of outcomes across the two groups.

Results

A total of 22 895 patients with bronchiectasis were identified. Following 1:2 PS matching, the final cohort consisted of 3137 individuals, with 1123 MMT receivers and 2014 macrolide non-receivers. MMT administration was associated with a significantly reduced risk of MACE (16.38 versus 24.11 events per 1000 person-years; hazard ratio (HR) 0.68, 95% CI 0.52–0.90). Importantly, the use of MMT was not associated with elevated risk of ventricular arrhythmias or sudden cardiac death (7.17 versus 7.67 events per 1000 person-years; HR 0.93, 95% CI 0.60–1.44).

Conclusions

The administration of MMT in patients with bronchiectasis was associated with a significant reduction in the risk of MACE, without any evidence suggesting an increased risk of severe arrhythmia-related adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BronchiectasisMacrolidesAnti-Bacterial AgentsCardiovascular DiseasesHumansMaleFemaleMiddle AgedAgedHong KongPropensity ScoreProportional Hazards ModelsArrhythmias, CardiacDeath, Sudden, CardiacCohort StudiesMyocardial InfarctionRetrospective StudiesAdult

Substanzen

MacrolidesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, The University of Hong Kong Shen Zhen Hospital, Shen Zhen, China.
  • Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong, China.
  • Adult Cystic Fibrosis Centre, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK.
  • Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University, Liverpool Heart and Chest Hospital, Liverpool, UK.
  • Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
  • Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.

ORCID-Profile: Tommaso Bucci, Christopher Tze-Wei Tsang, Freddy Frost

Förderung

  • Sanming Project of Medicine in Shenzen Municipality
  • HKU-SZH Fund for Shenzhen Key Medical Discipline

Zitieren

APA

Guo, R., Wat, D., Lam, S. H. M., Bucci, T., Tsang, C. T., Cai, A. P., Chan, Y. H., Ren, Q. W., Huang, J. Y., Zhang, J. N., Gu, W. L., Zhu, C. Y., Hung, Y. M., Frost, F., Lip, G. Y. H., & Yiu, K. H. (2025). Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis. European Respiratory Journal. https://doi.org/10.1183/13993003.01574-2024

Vancouver

Guo R, Wat D, Lam SHM, Bucci T, Tsang CT, Cai AP, et al. Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis. European Respiratory Journal. 2025. doi:10.1183/13993003.01574-2024

BibTeX
@article{Guo2025,
  author = {Guo, Ran and Wat, Dennis and Lam, Steven Ho Man and Bucci, Tommaso and Tsang, Christopher Tze-Wei and Cai, An-Ping and Chan, Yap-Hang and Ren, Qing-Wen and Huang, Jia-Yi and Zhang, Jing-Nan and Gu, Wen-Li and Zhu, Ching-Yan and Hung, Yik-Ming and Frost, Freddy and Lip, Gregory Y H and Yiu, Kai-Hang},
  title = {Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis},
  journal = {European Respiratory Journal},
  year = {2025},
  doi = {10.1183/13993003.01574-2024}
}
Kostenlos starten →